NIAID- VRC- Evaluating mRNA Vaccine Candidates and Capability Development

NIAID-VRC-评估 mRNA 候选疫苗和能力开发

• 批准号: 10722429
• 负责人: BARRY GAUSE
• 金额: $ 152.73万
• 依托单位: LEIDOS BIOMEDICAL RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-31 至 2022-08-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10722429
• 关键词: Clinic; Development; Enterovirus; Filovirus; HIV; Health; Human; Influenza; Laboratories; Mission; National Institute of Allergy and Infectious Disease; Phase I Clinical Trials; Preclinical Testing; RNA vaccine; Research; Research Support; Toxicology; United States National Institutes of Health; Vaccine Research; Vaccines; human disease; improved; meetings; prevent; research clinical testing; vaccine candidate; vaccine development

The Dale and Betty Bumpers Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), at the National Institutes of Health, was established to facilitate research in vaccine development and is dedicated to improving global human health through the rigorous pursuit of effective vaccines and treatments for human diseases. One of the key components of the VRC's mission involves the rapid advancement of promising candidates from the laboratory to the clinic. Meeting this mission necessitates the development and manufacturing of vaccines for toxicology, and Phase 1 clinical trials.

美国国立卫生研究院国家过敏和传染病研究所（NIAID）的Dale和Betty Bumpers疫苗研究中心（VRC）成立，旨在促进疫苗开发研究，并致力于通过严格追求有效的疫苗和人类疾病治疗来改善全球人类健康。VRC的使命的关键组成部分之一是将有前途的候选人从实验室迅速推向临床。满足这一使命需要开发和生产用于毒理学的疫苗，以及1期临床试验。